- Home
- ITGR vs GH Comparison
ITGR vs GH Comparison
Compare ITGR & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ITGR | GH |
|---|---|---|
| Founded | 1970 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 13.3B |
| IPO Year | 2000 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ITGR | GH |
|---|---|---|
| Price | $85.06 | $86.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 19 |
| Target Price | $91.14 | ★ $121.11 |
| AVG Volume (30 Days) | 685.1K | ★ 1.6M |
| Earning Date | 04-23-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ 2.89 | N/A |
| Revenue | ★ $1,853,637,000.00 | $982,021,000.00 |
| Revenue This Year | $1.69 | $33.40 |
| Revenue Next Year | $6.53 | $28.32 |
| P/E Ratio | $29.48 | ★ N/A |
| Revenue Growth | 7.98 | ★ 32.88 |
| 52 Week Low | $62.00 | $36.36 |
| 52 Week High | $127.56 | $120.74 |
Technical Indicators
Market Signals| Indicator | ITGR | GH |
|---|---|---|
| Relative Strength Index (RSI) | 49.02 | 42.00 |
| Support Level | $82.58 | $82.26 |
| Resistance Level | $88.36 | $90.28 |
| Average True Range (ATR) | 2.81 | 3.74 |
| MACD | 0.06 | 0.49 |
| Stochastic Oscillator | 37.89 | 51.50 |
Price Performance
Historical ComparisonAbout ITGR Integer Holdings Corporation
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns maximum of its revenue in the United States, and also has its presence in Ireland, Puerto Rico, Costa Rica, and Rest of the World.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.